Clinical treatment and small molecular drugs for anti MERS-CoV:research advances / 国际药学研究杂志

ABSTRACT

Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the newly identified MERS-CoV, which was first discovered in Saudi Arabia in 2012. Although most cases of MERS have occurred in Middle East, cases also have been reported in Europe, the USA and Asia in people who travelled from the Middle East or their contacts. The most recent outbreak was in South Korea with over dozens of cases, wherein, one case imported into mainland China via Hong Kong. No specific drug treatment exists for MERS now. Supportive treatment, aiming to prevent complications, supporting the function of respiratory, circulatory and renal, was the mainstay of management. In this paper, the reported clinical treatment, the research progress of potential targets and small molecule drugs for anti MERS-CoV were reviewed.